| Schedule of financial information by reportable segment |
The following is financial information relating to the Company's reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Six Months Ended |
|
|
December 31, |
|
December 31, |
|
|
2022 |
|
2021 |
|
2022 |
|
2021 |
Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
203,887 |
|
$ |
204,971 |
|
$ |
403,836 |
|
$ |
402,156 |
Diagnostics and Genomics |
|
|
68,003 |
|
|
64,527 |
|
|
137,907 |
|
|
125,512 |
Intersegment |
|
|
(309) |
|
|
(222) |
|
|
(507) |
|
|
(673) |
Consolidated net sales |
|
$ |
271,581 |
|
$ |
269,276 |
|
$ |
541,236 |
|
$ |
526,995 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
89,336 |
|
$ |
93,281 |
|
$ |
175,278 |
|
$ |
183,381 |
Diagnostics and Genomics |
|
|
8,296 |
|
|
10,880 |
|
|
16,934 |
|
|
18,344 |
Segment operating income |
|
$ |
97,632 |
|
$ |
104,161 |
|
$ |
192,212 |
|
$ |
201,725 |
Costs recognized on sale of acquired inventory |
|
|
(100) |
|
|
(84) |
|
|
(400) |
|
|
(1,595) |
Amortization of acquisition related intangible assets |
|
|
(19,125) |
|
|
(18,380) |
|
|
(38,408) |
|
|
(36,769) |
Impact of partially-owned consolidated subsidiaries(1) |
|
|
— |
|
|
(1,004) |
|
|
647 |
|
|
(2,567) |
Acquisition related expenses and other |
|
|
8,307 |
|
|
13,262 |
|
|
8,010 |
|
|
15,618 |
Eminence impairment |
|
|
— |
|
|
(18,715) |
|
|
— |
|
|
(18,715) |
Stock based compensation, inclusive of employer taxes |
|
|
(16,878) |
|
|
(14,815) |
|
|
(32,336) |
|
|
(28,675) |
Restructuring costs |
|
|
(780) |
|
|
(743) |
|
|
(2,950) |
|
|
(1,928) |
Corporate general, selling, and administrative expenses |
|
|
(1,165) |
|
|
(1,334) |
|
|
(2,567) |
|
|
(1,524) |
Consolidated operating income |
|
$ |
67,891 |
|
$ |
62,348 |
|
$ |
124,208 |
|
$ |
125,570 |
(1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of 2023.
|